Related Experiment Video

Updated: Jun 8, 2026

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells
08:12

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells

Published on: August 11, 2014

PKC-θ is a drug target for prevention of T cell-mediated autoimmunity and allograft rejection

Myung-Ja Kwon1, Ruiqing Wang, Jian Ma

  • 1Beckman Research Institute of the City of Hope, Duarte, CA 91010, Los Angeles, USA.

Endocrine, Metabolic & Immune Disorders Drug Targets
|October 7, 2010
PubMed

Insights

Protein kinase C theta (PKC-θ) is crucial for T cell receptor (TCR) signaling and immune responses. Inhibiting PKC-θ may prevent autoimmune diseases and transplant rejection by modulating T cell activation and differentiation.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Signaling

Background:

  • Protein kinase C theta (PKC-θ) is a key mediator of T cell receptor (TCR) signaling.
  • PKC-θ activation is essential for the translocation to immunological synapses and regulation of transcription factors like NFκB, AP-1, and NFAT.

Purpose of the Study:

  • To elucidate the role of PKC-θ in T cell activation, survival, and differentiation.
  • To explore the therapeutic potential of selective PKC-θ inhibition in autoimmune diseases and allograft rejection.

Main Methods:

  • Investigated T cell activation, survival, and differentiation in PKC-θ deficient T cells.
  • Utilized in vitro and in vivo models to assess T cell function and inflammatory responses.

Main Results:

  • T cells deficient in PKC-θ exhibit impaired T cell activation, survival, and activation-induced cell death.
  • PKC-θ deficiency leads to defects in the differentiation of inflammatory T helper cells, including Th2 and Th17 cells.

Conclusions:

  • PKC-θ plays a critical role in T cell-mediated immune responses and the development of autoimmunity.
  • Selective inhibition of PKC-θ represents a promising therapeutic strategy for autoimmune diseases and preventing allograft rejection.

More Related Videos

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...